LARTRUVO (olaratumab injection, 10 mg/mL) in combination with doxorubicin received an FDA accelerated approval for the treatment of adults with soft tissue sarcoma with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
